Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists - PubMed (original) (raw)
Affiliations
- PMID: 16513620
Free article
Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists
Renzo Cescato et al. J Nucl Med. 2006 Mar.
Free article
Abstract
The uptake of radiolabeled somatostatin analogs by tumor cells through receptor-mediated internalization is a critical process for the in vivo targeting of tumoral somatostatin receptors. In the present study, the somatostatin receptor internalization induced by a variety of somatostatin analogs was measured with new immunocytochemical methods that allow characterization of trafficking of the somatostatin receptor subtype 2 (sst2), somatostatin receptor subtype 3 (sst3), and somatostatin receptor subtype 5 (sst5) in vitro at the protein level.
Methods: Human embryonic kidney 293 (HEK293) cells expressing the sst2, sst3, or the sst5 were used in a morphologic immunocytochemical internalization assay using specific sst2, sst3 and sst5 antibodies to qualitatively and quantitatively determine the capability of somatostatin agonists or antagonists to induce somatostatin receptor internalization. In addition, the internalization properties of a selection of these agonists have been compared and quantified in sst2-expressing CHO-K1 cells using an ELISA.
Results: Agonists with a high sst2-binding affinity were able to induce sst2 internalization in the HEK293 and CHO-K1 cell lines. New sst2 agonists, such as Y-DOTA-TATE, Y-DOTA-NOC, Lu-DOTA-BOC-ATE (where DOTA is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; TATE is [Tyr3, Thr8]-octreotide; NOC is [1-NaI3]-octreotide; and BOC-ATE is [BzThi3, Thr8]-octreotide), iodinated sugar-containing octreotide analogs, or BIM-23244 were considerably more potent in internalizing sst2 than was DTPA-octreotide (where DTPA is diethylenetriaminepentaacetic acid). Similarly, compounds with high sst3 affinity such as KE108 were able to induce sst3 internalization. In sst2- or sst3-expressing cell lines, agonist-induced receptor internalization was efficiently abolished by sst2- or sst3-selective antagonists, respectively. Antagonists alone had no effect on sst2 or sst3 internalization. We also showed that somatostatin-28 and somatostatin-14 can induce sst5 internalization. Unexpectedly, however, potent sst5 agonists such as KE108, BIM-23244, and L-817,818 were not able to induce sst5 internalization under the same conditions.
Conclusion: Using sensitive and reproducible immunocytochemical methods, the ability of various somatostatin analogs to induce sst2, sst3, and sst5 internalization has been qualitatively and quantitatively determined. Whereas all agonists triggered sst2 and sst3 internalization, sst5 internalization was induced by natural somatostatin peptides but not by synthetic high-affinity sst5 agonists. Such assays will be of considerable help for the future characterization of ligands foreseen for nuclear medicine applications.
Comment in
- Receptor radionuclide therapy of tumors: a road from basic research to clinical applications.
Bodei L, Paganelli G, Mariani G. Bodei L, et al. J Nucl Med. 2006 Mar;47(3):375-7. J Nucl Med. 2006. PMID: 16513604 No abstract available.
Similar articles
- Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR. Reubi JC, et al. Eur J Nucl Med. 2000 Mar;27(3):273-82. doi: 10.1007/s002590050034. Eur J Nucl Med. 2000. PMID: 10774879 - [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Siehler S, Seuwen K, Hoyer D. Siehler S, et al. Eur J Pharmacol. 1998 May 8;348(2-3):311-20. doi: 10.1016/s0014-2999(98)00159-9. Eur J Pharmacol. 1998. PMID: 9652348 - New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Ginj M, Zhang H, Eisenwiener KP, Wild D, Schulz S, Rink H, Cescato R, Reubi JC, Maecke HR. Ginj M, et al. Clin Cancer Res. 2008 Apr 1;14(7):2019-27. doi: 10.1158/1078-0432.CCR-07-1687. Clin Cancer Res. 2008. PMID: 18381940 - Drug design at peptide receptors: somatostatin receptor ligands.
Hannon JP, Nunn C, Stolz B, Bruns C, Weckbecker G, Lewis I, Troxler T, Hurth K, Hoyer D. Hannon JP, et al. J Mol Neurosci. 2002 Feb-Apr;18(1-2):15-27. doi: 10.1385/JMN🔞1-2:15. J Mol Neurosci. 2002. PMID: 11931345 Review. - [New medical treatments in pituitary adenomas].
Drutel A, Caron P, Archambeaud F. Drutel A, et al. Ann Endocrinol (Paris). 2008 Sep;69 Suppl 1:S16-28. doi: 10.1016/S0003-4266(08)73964-7. Ann Endocrinol (Paris). 2008. PMID: 18954854 Review. French.
Cited by
- PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India.
Sharma P, Singh H, Bal C, Kumar R. Sharma P, et al. Indian J Nucl Med. 2014 Jan;29(1):2-12. doi: 10.4103/0972-3919.125760. Indian J Nucl Med. 2014. PMID: 24591775 Free PMC article. Review. - Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors.
Vedvyas Y, Shevlin E, Zaman M, Min IM, Amor-Coarasa A, Park S, Park S, Kwon KW, Smith T, Luo Y, Kim D, Kim Y, Law B, Ting R, Babich J, Jin MM. Vedvyas Y, et al. JCI Insight. 2016 Nov 17;1(19):e90064. doi: 10.1172/jci.insight.90064. JCI Insight. 2016. PMID: 27882353 Free PMC article. - ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
Ambrosini V, Campana D, Tomassetti P, Fanti S. Ambrosini V, et al. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S52-60. doi: 10.1007/s00259-011-1989-4. Eur J Nucl Med Mol Imaging. 2012. PMID: 22388622 Review. - Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with 111In in HEPES and MES buffer.
Brom M, Joosten L, Oyen WJ, Gotthardt M, Boerman OC. Brom M, et al. EJNMMI Res. 2012 Jan 27;2:4. doi: 10.1186/2191-219X-2-4. EJNMMI Res. 2012. PMID: 22284727 Free PMC article. - In vitro cytotoxic and genotoxic evaluation of peptides used in nuclear medicine (DOTATATE and Ubiquicidin29-41) in CHO-K1 cells.
Ocampo IZ, de Queiroz Souza Passos P, Ramirez de Carvalho L, Lira da Cruz CA, Esteves-Pedro NM, Medeiros da Silva F, Higa OZ, Dias LA, Okazaki K, Vieira DP. Ocampo IZ, et al. Cytotechnology. 2016 Dec;68(6):2301-2310. doi: 10.1007/s10616-016-0024-9. Epub 2016 Sep 29. Cytotechnology. 2016. PMID: 27686814 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous